Ventris Medical Announces Company Launch, Introduces New Amnion Product
Newport Beach, CA – January 9, 2018 – Ventris Medical, a Newport Beach-based healthcare company, today announced the company’s official launch. The company also is launching its full line of placental allograft products that will be used in surgical and non-surgical applications.
The product launch includes the full line of Cellesta™ branded products, which will be available to facilities throughout the US in both flowable and sheet forms. Conveniently shelf-stable and stored at ambient temperature, Cellesta™ can be used in a variety of applications including general surgery, plastic surgery, wound care, urologic and orthopedic procedures. Ventris will focus on quality, donor selection, tissue recovery, and processing protocols and adhere to the strictest tissue banking standards. The company is dedicated to providing products with the highest level of efficacy and the ultimate goal of exceptional outcomes for the patient.
Ventris Medical is a new company headed by Russell Cook, a well-established entrepreneur with more than 15 years of experience in developing companies focused on the field of biologics. He previously founded several successful start-ups, including Summit Surgical, Radius Medical (acquired by NuVasive) and Biostructures (acquired by Bioventus). He has been granted three patents for unique, novel bone graft substitutes, materials, and methods, and he continues to work on the development of additional products in the healthcare landscape. Cook embodies a deep understanding of sales, distribution, and product development activities critical to a successful medical start-up.
The Ventris Medical line of placental allograft products will be regulated by the FDA Center for Biologics Evaluation and Research (CBER), which regulates human cells, tissues, and cellular and tissue-based products (HCT/Ps). Ventris adheres to Current Good Tissue Practices, focusing extensively on donor eligibility and the recovery process. Cellesta™ amniotic products are regulated under 21 CFR Part 1270 and 21 CFR Part 1271 and Section 361 of the Public Health Services Act.
Cellesta™ is a minimally manipulated amnion product that is delivered in both membrane and flowable forms. All Cellesta™ products are processed using Clearant™, Ventris’ proprietary, gentle preservation technology, to ensure optimal viability with minimal protein degradation.
About Ventris Medical
Ventris Medical manages the supply chain of placental allograft products from the origin of the tissue all the way through its clinical application. Cellesta™ amnion products are immediately harvested, responsibly maintained, and efficiently supplied to the customer. Above all else, Ventris Medical is dedicated to patient safety with its highly controlled regulatory environment and quality assured processing protocols. For more information, visit www.ventrismedical.com.
The views and opinions expressed in this blog are solely those of the author, and do not represent the views of WoundSource, Kestrel Health Information, Inc., its affiliates, or subsidiary companies.